PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.
Location: United States, New York
Employees: 51-200
Founded date: 2014
Mentions in press and media 21
| Date | Title | Description |
| 13.09.2024 | The Battle Against Esophageal Cancer: A New Era of Early Detection | Esophageal cancer is a silent predator. It lurks in the shadows, often undetected until it’s too late. However, a new dawn is breaking in the fight against this formidable foe. Lucid Diagnostics Inc. is stepping into the spotlight, armed wi... |
| 10.09.2024 | Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress | Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK, Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company&q... |
| 03.09.2024 | Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health | Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Luci... |
| 15.08.2024 | PAVmed's Path to Progress: A Dual Focus on Financial Stability and Cancer Prevention | PAVmed Inc. is navigating the complex waters of the medical technology industry. With a focus on diagnostics and digital health, the company is not just a player; it’s a contender. Recent updates reveal a dual strategy: enhancing financial ... |
| 13.08.2024 | PAVmed Provides Business Update and Second Quarter 2024 Financial Results | Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX Program Veris Health actively pursuing financing following launch of pilot program with ... |
| 13.08.2024 | The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer | Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"... |
| 06.08.2024 | Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing | Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" ... |
| 23.07.2024 | Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume | Quarterly EsoGuard® test volume increased 31 percent sequentially NEW YORK, July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical di... |
| 02.07.2024 | Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population | Prospective screening study demonstrates excellent EsoGuard sensitivity of 87.5% and negative predictive value (NPV) of 98.6% Previously announced positive data from a separate prospective VA screening study also accepted for peer-reviewed ... |
| 13.06.2024 | PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | First patients enrolled on the Veris Cancer Care Platform NEW YORK, June 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operatin... |
Show more